Physician profile
Jason Slate
NPI 1275648586
$1,153.86
in general payments reported to CMS, 2019-2025
17 companies · $250 in 2025
The $250 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $46.50 · 2021: $20.87 · 2022: $20.03 · 2023: $303 · 2024: $513 · 2025: $250.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,058 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,058.01 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $199.83 | 2023-2024 | Rinvoq, Skyrizi |
| Boston Scientific Corporation | $159.65 | 2021-2024 | Exalt Model D |
| Janssen Scientific Affairs, LLC | $121.25 | 2024 | Stelara |
| Phathom Pharmaceuticals, INC. | $120.71 | 2024-2025 | Voquezna |
| Janssen Biotech, INC. | $113.13 | 2023-2025 | Stelara, Remicade, Simponi Aria |
| Exact Sciences Corporation | $107.78 | 2024 | Cologuard Collection Kit |
| Madrigal Pharmaceuticals | $70.04 | 2025 | Rezdiffra |
| Ardelyx, INC. | $48.06 | 2024 | Ibsrela |
| Merck Sharp & Dohme LLC | $43.31 | 2023-2024 | Dificid, Zinplava |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $38.80 | 2023-2024 | Xifaxan, Trulance |
| Ferring Pharmaceuticals INC. | $27.11 | 2020 | |
| Genzyme Corporation | $20.03 | 2022 | |
| Ironwood Pharmaceuticals, INC | $19.39 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.56 | 2025 | Entyvio |
| Qol Medical, LLC | $16.62 | 2023 | Sucraid |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $15.06 | 2025 | Omvoh |
| Braintree Laboratories, INC. | $14.53 | 2023 | Suflave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Slate listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.